Back to discover

Protein / target

Proto-oncogene tyrosine-protein kinase receptor Ret

Encoded byRETP07949Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
12
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Transmembrane receptor protein tyrosine kinase

Strongest disease association

multiple endocrine neoplasia type 2A

Via encoding gene RET · Genetic evidence · score 0.94

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15).

View complete UniProt function annotation

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation (PubMed:21994944, PubMed:23333276, PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), triggering RET autophosphorylation and activation, leading to activation of downstream signaling pathways, including the MAPK- and AKT-signaling pathways (PubMed:21994944, PubMed:23333276, PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 signaling: in the presence of the ligand GDNF in somatotrophs within pituitary, promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF (PubMed:20616503, PubMed:21994944). Required for the molecular mechanisms orchestration during intestine organogenesis via the ARTN-GFRA3 signaling: involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue (By similarity). Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed:28846097, PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner (PubMed:20702524, PubMed:21357690). Also active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage (PubMed:21357690). Triggers the differentiation of rapidly adapting (RA) mechanoreceptors (PubMed:20064382). Involved in the development of the neural crest (By similarity). Regulates nociceptor survival and size (By similarity). Phosphorylates PTK2/FAK1 (PubMed:21454698)

Subcellular location

Cell membraneEndosome membrane
Domains and Gene Ontology detail (34)

Domains & features

CadherinProtein kinase

Gene Ontology

  • Caxon
  • Cendosome membrane
  • Cplasma membrane
  • Cplasma membrane protein complex
  • Creceptor complex
  • FATP binding
  • Fcalcium ion binding
  • Fprotein tyrosine kinase activity
  • Fsignaling receptor activity
  • Ftransmembrane receptor protein tyrosine kinase activity
  • Paxon guidance
  • Pcell surface receptor protein tyrosine kinase signaling pathway

1114 aa · 124 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Receptor tyrosine kinase signallingUniProt · GOCell migrationUniProt · GOCell adhesionUniProt · GO
View supporting evidence

Receptor tyrosine kinase signalling

  • ·Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell…
  • ·transmembrane receptor protein tyrosine kinase activity
  • ·cell surface receptor protein tyrosine kinase signaling pathway

Cell migration

  • ·Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell…
  • ·positive regulation of cell migration

Cell adhesion

  • ·Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell…
  • ·homophilic cell-cell adhesion
  • ·neuron cell-cell adhesion
  • ·positive regulation of cell adhesion mediated by integrin
View underlying pathways (5)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

GFRA2GFRA1NRTNGFRA3ARTNGDNFGFRALPSPNNCOA4CCDC6RET

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

3 medicines · 6 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Carcinoma, Non-Small-Cell Lung1 medicine
Carcinoma, Renal Cell1 medicine
Colorectal Neoplasms1 medicine
Gastrointestinal Stromal Tumors1 medicine
Neuroendocrine Tumors1 medicine
Broader indication categories (1)

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

12 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

pralsetinib
Narrow target profileApprovedInhibitor

Tyrosine-protein kinase receptor RET inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

sunitinib
ApprovedInhibitor

Tyrosine-protein kinase receptor RET inhibitor

Indicated for Carcinoma, Renal Cell, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, Neoplasms

Direct interaction with this protein · 1 of 9 recorded protein targets — broad pharmacology

regorafenib
ApprovedInhibitor

Tyrosine-protein kinase receptor RET inhibitor

Indicated for Colorectal Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 18 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene RET

Gene-level evidence surfaced through the gene RETthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Medullary thyroid gland carcinoma
0.99Well supported

Genetic evidence dominant · Open Targets 0.86

Pheochromocytoma
0.96Well supported

Genetic evidence dominant · Open Targets 0.78

multiple endocrine neoplasia type 2A
0.95Well supported

Genetic evidence dominant · Open Targets 0.86

Multiple endocrine neoplasia type 2
0.94Well supported

Genetic evidence dominant · Open Targets 0.77

Hirschsprung disease
0.91Well supported

Genetic evidence dominant · Open Targets 0.79

View evidence synthesis (5)
Medullary thyroid gland carcinomaWell supported
0.99
agreement 0.911.00
Genetic40%Clinical30%Somatic mutation17%Literature6%Animal model6%Genetic literaturedup

Open Targets aggregate 0.86 · 5 independent evidence families · 1 not counted as duplicate

PheochromocytomaWell supported
0.96
agreement 0.871.00
Genetic61%Somatic mutation23%Literature9%Clinical8%Genetic literaturedup

Open Targets aggregate 0.78 · 4 independent evidence families · 1 not counted as duplicate

multiple endocrine neoplasia type 2AWell supported
0.95
agreement 0.811.00
Genetic93%Literature7%Genetic literaturedup

Open Targets aggregate 0.86 · 2 independent evidence families · 1 not counted as duplicate

Multiple endocrine neoplasia type 2Well supported
0.94
agreement 0.811.00
Genetic75%Animal model21%Literature4%Genetic literaturedup

Open Targets aggregate 0.77 · 3 independent evidence families · 1 not counted as duplicate

Hirschsprung diseaseWell supported
0.91
agreement 0.791.00
Genetic64%Animal model28%Literature8%Genetic literaturedup

Open Targets aggregate 0.79 · 3 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Medullary thyroid gland carcinoma0.86
multiple endocrine neoplasia type 2A0.86
multiple endocrine neoplasia type 2B0.83
Hirschsprung disease0.79
Pheochromocytoma0.78
Multiple endocrine neoplasia type 20.77
Familial medullary thyroid carcinoma0.76
Carcinoma, Non-Small-Cell Lung0.71
Carcinoma, Hepatocellular0.69
Multiple endocrine neoplasia0.67

Drug development

16 compounds recorded · 12 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
SELPERCATINIBApproval
ALECTINIBApproval
SORAFENIB TOSYLATEApproval
SORAFENIBApproval
BOS-589Phase 2
QUIZARTINIBApproval
VANDETANIBApproval
SUNITINIB MALATEApproval
MOTESANIBPhase 3
CEP-32496Phase 1 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (11)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via regorafenib · NCT05395741

ACTIVE_NOT_RECRUITING · via sunitinib · NCT02465060

ACTIVE_NOT_RECRUITING · via sunitinib · NCT01396408

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Withdrawn from market2024-10-24

    Market withdrawal: Gavreto (EMA)

    ema · market · ema · via pralsetinib

  2. New publication2024-06-04
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 69 citations · Europe PMC · via regorafenib

  3. New publication2024-05-03
    Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.

    PLoS computational biology · 2024 · 10 citations · Europe PMC · via sunitinib

  4. New publication2024-01-05
    Genomic profiling in GIST: Implications in clinical outcome and future challenges.

    Neoplasia (New York, N.Y.) · 2024 · 20 citations · Europe PMC · via sunitinib

  5. New publication2021-03-01
    Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2021 · 1,297 citations · Europe PMC · via sunitinib

  6. Regulatory approval2021-02-11

    Approval: Sunitinib Accord (EMA)

    ema · regulatory · ema · via sunitinib

  7. New publication2019-02-16
    Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2019 · 2,427 citations · Europe PMC · via sunitinib

  8. New publication2018-03-21
    Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

    The New England journal of medicine · 2018 · 3,404 citations · Europe PMC · via sunitinib

  9. New publication2016-12-06
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet (London, England) · 2017 · 2,767 citations · Europe PMC · via regorafenib

  10. Regulatory approval2013-08-26

    Approval: Stivarga (EMA)

    ema · regulatory · ema · via regorafenib

  11. Regulatory approval2006-07-19

    Approval: Sutent (EMA)

    ema · regulatory · ema · via sunitinib

  12. New publication2005-12-05
    Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2006 · 1,110 citations · Europe PMC · via sunitinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.